Clinical Trial Update: To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating afatinib for advanced lung squamous cell carcinoma with EGFR sensitive mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Squamous Cell Carcinoma

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Lung Squamous Cell Carcinoma | Phase 4 | Status: UNKNOWN